Pharmaceuticals, Biotechnology and Life Sciences
Esperite N.V. has announced a €1 million private placement of 100 convertible notes with a principal amount of €10,000 each, with share subscription warrants attached (the “First Tranche Notes and Warrants”).
U.S. Food and Drug Administration(FDA) has accepted for review the Alexion Pharmaceuticals’s supplemental Biologics License Application (sBLA) to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
OptiBiotix health has signed a manufacturing, supply, and profit sharing deal with Sacco, one of Europe’s leading suppliers of probiotics ingredients.
Valisek, a joint venture between ValiRx, a clinical stage biotechnology company and Tangent Reprofiling Limited, plans to add a third clinical site, in Tbilisi, Georgia.
Notable news in the pharmaceutical and biotech markets includes a slew of mergers and acquisitions, new drug trails and product launches as industry leaders search for competitive advantage and increased revenue streams.
Innate Pharma has reported its consolidated financial results for the year ended December 31, 2016.
Swedish Orphan Biovitrum AB known as Sobi said Tuesday that the FDA has approved increased shelf life and extended out-of-refrigeration for Orfadin capsules.
IDMC has recommended that all three doses continue to be tested in the ongoing Phase 2b trial for BGS-649, an inhibitor for obese men with hypogonadotropic hypoganadism.
Belgian-headquartered biopharmaceutical company TiGenix has received positive feedback from the U.S. Food and Drug Administration (FDA) for its improved phase III trial for the treatment of complex perianal fistulas in Crohn’s disease patients.
Biohaven Pharmaceutical, a privately-held, clinical stage biopharmaceutical company focused neurological diseases, has completed the second tranche of its previously disclosed $80 million private financing, and has welcomed new board members, which saw one board member step down.